Industry Briefs: Feb. 13, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Feb. 13, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Bend Research has entered into a licensing agreement with Eli Lilly, under which Bend Research will make its proprietary spray-dried dispersion technology available to Lilly. Read More

BioDiem has licensed its live attenuated influenza virus (LAIV) vaccine technology to China-based Changchun BCHT Biotechnology. Read More

Carbogen Amcis has announced that its Bubendorf, Switzerland, API-manufacturing site has successfully completed a September 2011 FDA cGMP inspection. Read More

Discovery Labs has entered into a definitive agreement with Lacey Manufacturing, a unit of Precision Engineered Products, to manufacture and supply product for the commercial introduction of Afectair, a series of proprietary ventilator circuit–patient interface connectors and related componentry for the delivery of inhaled therapies to patients requiring ventilatory support. Read More

Quintiles has launched two services—Strategic Drug Development and Consulting at Quintiles—for the development and commercialization of new medications in Asia. Read More

Valeant Pharmaceuticals has agreed to acquire the ophthalmic biotechnology company Eyetech. Read More

People News

Cobra Biologics has appointed Sharon Brownlow and Partick Lansky as business development managers, and added nonexecutive directors Elisabeth Lindner, Carl Johan Sundberg, and Jinyue Wang, to its board. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here